Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease

Table 4 Treatment persistence subgroup analysis in patients with ulcerative colitis and Crohn’s disease, n (%)

Inflammatory bowel disease subtype			Treatment persistence by 30 months	Treatment discontinuation by 30 months	Total	P value
Ulcerative colitis	Drug group	Biosimilar	31 (86.1)	5 (13.9)	36	1.0
		Originator	7 (87.5)	1 (12.5)	8
	Total		36	6	44
Crohn’s disease	Drug group	Biosimilar	170 (88.5)	22 (11.5)	192	0.400
		Originator	29 (82.9)	6 (17.1)	35
	Total		199	28	227
Total	Drug group	Biosimilar	201 (88.2)	27 (11.8)	228	0.451
		Originator	36 (83.7)	7 (16.3)	43
	Total		237	34	271